8-K: CervoMed's Neflamapimod Shows Promise in Slowing Dementia with Lewy Bodies Progression in Phase 2b Extension Study

CervoMed announces positive clinical trial results from the extension phase of its RewinD-LB Phase 2b study, indicating that neflamapimod slows clinical progression in patients with dementia with Lewy bodies (DLB).

Summary

• CervoMed's RewinD-LB Phase 2b clinical trial extension phase results show that neflamapimod has a clinically meaningful effect on slowing clinical progression in patients with DLB.
• The study compared patients receiving new capsules of neflamapimod to those receiving old capsules, which served as a control, and to placebo data from the initial phase.
• Results from the first 16 weeks of the extension phase demonstrated improvement on the primary outcome measure, change in CDR-SB, with the new capsules compared to both old capsules (p<0.001) and placebo (p=0.003).
• The magnitude of the effect on the CDR-SB was a mean improvement of 0.73 points with the new capsules compared to the old capsules.
• In participants whose screening plasma ptau181 was less than 2.2 pg/mL, the mean improvement was 0.81 points.
• The percentage of participants who had clinically meaningful worsening (increased >= 1.5 points on the CDR-SB) during the first 16 weeks of the Extension phase was 40% lower on a relative basis (26.8% vs. 45.1%) in New Capsule recipients compared to Old Capsule recipients.
• Improvement was also seen on the Alzheimers Disease Cooperative Study (ADCS)-CGIC in participants administered New Capsules both in comparison to Old Capsules (p=0.035) during the Extension phase and in a within-participant comparison to placebo treatment during the Initial phase (p=0.039).
• The study also showed a lower incidence of falls with the New Capsules (4% vs. 15.2% with Old Capsules during the Extension phase, p=0.025, and 19.7% with placebo in the Initial phase, p=0.007) in participants with screening ptau181 < 2.2 pg/mL.
• CervoMed expects to complete the full 32-weeks of the Extension phase of the RewinD-LB study and engage with regulatory authorities to discuss finalizing Phase 3 plans for neflamapimod after these additional data become available later in 2025.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results, suggesting potential for neflamapimod as a treatment for DLB. The management's comments are optimistic, and the study's design includes a control group, strengthening the findings. However, the study is still ongoing, and future results and regulatory approval are uncertain.

Positives

• Neflamapimod shows promise in slowing clinical progression in patients with DLB.
• The study demonstrated statistically significant improvements in CDR-SB and ADCS-CGIC with the new capsules compared to controls.
• The drug appears to be safe and well-tolerated, with no new safety signals identified.
• There was a lower incidence of falls observed with the new capsules.

Risks

• The study results are from the first 16 weeks of the extension phase, and the full 32-week data is still pending.
• The company needs to acquire sufficient funding for any Phase 3 trial of neflamapimod in DLB.
• The forward-looking statements are subject to risks and uncertainties, including those related to clinical trial results, regulatory approval, and economic conditions.

Future Outlook

CervoMed expects to complete the full 32-weeks of the Extension phase of the RewinD-LB study and engage with regulatory authorities to discuss finalizing Phase 3 plans for neflamapimod after these additional data become available later in 2025.

Management Comments

• Stephen Gomperts, MD, PhD, stated that the RewinD-LB Extension phase results for neflamapimod are highly encouraging and validate prior clinical trial results.
• John Alam, MD, CEO of CervoMed, believes that neflamapimod has the potential to be a transformative therapy for patients with DLB.

Industry Context

The announcement is significant as it provides further evidence for the potential of neflamapimod as a treatment for DLB, a neurodegenerative disorder with limited treatment options. The positive results could position CervoMed as a key player in the development of therapies for this condition.

Comparison to Industry Standards

• The 0.73 point improvement on the CDR-SB with the new capsules compared to the old capsules exceeds the 0.5-point treatment group difference considered to be clinically meaningful, as referenced by Tarawneh and Pankratz, Alzheimers Res Ther 2024;16:3.
• Other companies developing treatments for DLB include Denali Therapeutics and Biogen, but CervoMed's approach with neflamapimod, targeting synaptic dysfunction, is distinct.

Stakeholder Impact

• Positive results could benefit shareholders by increasing the company's value.
• Successful development of neflamapimod could provide a new treatment option for patients with DLB and their families.
• Positive results could attract potential partners and investors.

Next Steps

• Complete the full 32-weeks of the Extension phase of the RewinD-LB study.
• Engage with regulatory authorities to discuss finalizing Phase 3 plans for neflamapimod.
• Present the Extension phase data at AD/PD 2025.

Key Dates

Keywords

neflamapimod, dementia with Lewy bodies, DLB, RewinD-LB, clinical trial, CervoMed, CDR-SB, ADCS-CGIC, Alzheimers, neurologic disorders